Effects of acute lorazepam administration on aminergic activity in normal elderly subjects: Relationship to performance effects and apolipoprotein genotype

Neurochemical Research

Volumn 29, Issue 7, 2004, Pages 1391-1398

  Pomara, Nunzio ^a,b   Willoughby, Lisa M ^b   Hashim, Audrey ^a   Sershen, Henry ^a   Sidtis, John J ^a,b   Wesnes, Keith ^c   Greenblatt, David J ^d   Lajtha, Abel ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Cognitive Treatment Research Ltd ^*  (United Kingdom)

^d TUFTS UNIVERSITY   (United States)

Author keywords

5 HIAA; APOE; Elderly; HVA; Lorazepam; Memory; MHPG

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN EPSILON4; HOMOVANILLIC ACID; LORAZEPAM; MONOAMINE; PLACEBO; UNCLASSIFIED DRUG; ANXIOLYTIC AGENT; APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

ACUTE DRUG ADMINISTRATION; ADULT; AGED; ALLELE; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG INDUCED DISEASE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MEMORY; MENTAL PERFORMANCE; MOTOR DYSFUNCTION; NORMAL HUMAN; PERFORMANCE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SENESCENCE; TIME; ANALYSIS OF VARIANCE; BLOOD; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; MOTOR ACTIVITY; PHYSIOLOGY; REGRESSION ANALYSIS;

AGED; ANALYSIS OF VARIANCE; ANTI-ANXIETY AGENTS; APOLIPOPROTEIN E4; APOLIPOPROTEINS; APOLIPOPROTEINS E; COGNITION; COGNITION DISORDERS; GENOTYPE; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; LORAZEPAM; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; MOTOR ACTIVITY; REGRESSION ANALYSIS;

EID: 3442895663     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NERE.0000026402.09466.54     Document Type: Article

References (41)

1. Pomara, N., Deptula, D., Medel, M., Block, R. I., and Greenblatt, D. J. 1989. Effects of diazepam on recall memory: relationship to aging, dose, and duration of treatment. Psychopharmacol. Bull. 25:144-148.
2. Pomara, N., Tun, H., DaSilva, D., Hernando, R., Deptula, D., and Greenblatt, D. J. 1998. The acute and chronic performance effects of alprazolam and lorazepam in the elderly: Relationship to duration of treatment and self-rated sedation. Psychopharmacol. Bull. 34:139-153.
3. Mohler, H., Fritschy, J. M., and Rudolph, U. 2002. A new benzodiazepine pharmacology. J. Pharmacol. Exp. Ther. 300:2-8.
4. Costa, E. 1998. From GABAA receptor diversity emerges a unified vision of GABAergic inhibition. Annu. Rev. Pharmacol. Toxicol. 38, 321-350.
5. Arnsten, A. F. T. 1998. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cognit. Sci. 2:436-447.
6. Beatty, W. W. and Rush, J. R. 1983. Spatial working memory in rats: Effects of monoaminergic antagonists. Pharmacol. Biochem. Behav. 18:7-12.
7. Kahn, R. S., Harvey, P. D., Davidson, M., Keefe, R. S., Apter, S., Neale, J. M., Mohs, R. C., and Davis, K. L. 1994. Neuropsychological correlates of central monoamine function in chronic schizophrenia: Relationship between CSF metabolites and cognitive function. Schizophr. Res. 11:217-224.
8. Wolfe, N., Katz, D. I., Albert, M. L., Almozlino, A., Durso, R., Smith, M. C., and Volicer, L. 1990. Neuropsychological profile linked to low dopamine: In Alzheimer's disease, major depression, and Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 53:915-917.
9. di Rocco, A., Bottiglieri, T., Dorfman, D., Werner, P., Morrison, C., and Simpson, D. 2000. Decreased homovanillic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1-infected patients. Clin. Neuropharmacol. 23:190-194.
10. Amin, F., Seeman, T. E., Mohs, R. C., Davidson, M., Knott, P., Berkman, L. F., Albert, M., and Blazer, D. 1994. Plasma homovanillic acid and performance on motor and cognitive tasks in community-dwelling elderly: MacArthur studies of successful aging. Neuropsychopharmacology 10:29-35.
11. Invernizzi, R., Pozzi, L., and Samanin, R. 1991. Release of dopamine is reduced by diazepam more in the nucleus accumbens than in the caudate nucleus of conscious rats. Neuropharmacology 30:575-578.
12. Bowers, M. B., Jr., Hoffman, F. J., Jr., and Morton, J. B. 1991. Diazepam and haloperidol. Effect on regional brain homovanillic acid levels. Neuropsychopharmacology 5:65-69.
13. Singhal, R. L., Rastogi, R. B., and Lapierre, Y. D. 1983. Diazepam potentiates the effect of neuroleptics on behavioral activity as well as dopamine and norepinephrine turnover: Do benzodiazepines have antipsychotic potency? J. Neural Transm. 56:127-138.
14. Hellevuo, K., Kiianmaa, K., and Juhakoski, A. 1987. Effects of barbital and lorazepam in the AT and ANT rats: Motor performance and brain monoamine functions. Alcohol Alcohol Suppl 1:647-651.
15. Wolf, P., Olpe, H. R., Avrith, D., and Haas, H. L. 1978. GABAergic inhibition of neurons in the ventral tegmental area. Experientia 34:73-74.
16. Brose, N., O'Neill, R. D., Boutelle, M. G., and Fillenz, M. 1988. Dopamine in the basal ganglia and benzodiazepine-induced sedation. Neuropharmacology 27:589-595.
17. Bowers, M. B., Jr., and Morton, J. B. 1992. Diazepam antagonizes effects on dopamine metabolism produced by PCP receptor agonists. Prog. Neuropsychopharmacol. Biol. Psychiatry 16:211-215.
18. Coco, M. L., Kuhn, C. M., Ely, T. D., and Kilts, C. D. 1992. Selective activation of mesoamygdaloid dopamine neurons by conditioned stress: Attenuation by diazepam. Brain Res. 590:39-47.
19. Keller, H. H., Schaffner, R., and Haefely, W. 1976. Interaction of benzodiazepines with neuroleptics at central dopamine neurons. Naunyn Schmiedebergs Arch. Pharmacol. 294:1-7.
20. Hegarty, A. A. and Vogel, W. H. 1995. The effect of acute and chronic diazepam treatment on stress-induced changes in cortical dopamine in the rat. Pharmacol. Biochem. Behav. 52:771-778.
21. Reinhard, J. F., Jr., Bannon, M. J., and Roth, R. H. 1982. Acceleration by stress of dopamine synthesis and metabolism in prefrontal cortex: Antagonism by diazepam. Naunyn Schmiedebergs Arch. Pharmacol. 318:374-377.
22. Vachon, L. and Roberge, A. G. 1983. Effects of chloridazepoxide administration on biogenic amines in cat brain. Can. J. Physiol. Pharmacol. 61:81-88.
23. Haleem, D. J., and Batool, F. 1996. Regionally specific effects of diazepam on brain serotonin metabolism in rats: Sustained effects following repeated administration. Life Sci. 59:E239-E246.
24. Wolkowitz, O. M. et al. 1988. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results. Arch. Gen. Psychiatry 45:664-671.
25. Santagostino, G. et al. 1998. The influence of alprazolam on the monoaminergic neurotransmitter systems in dysthymic patients. Relationship to clinical response. Pharmacopsychiatry 31:131-136.
26. Zemishlany, Z., Davidson, M., Jaff, S., and McQueeney, R. 1991. Acute administration of alprazolam has no effect on plasma homovanillic acid concentration in normal subjects. Schizophr. Res. 5:81-83.
27. Wingerson, D. K., Cowley, D. S., Kramer, G. L., Petty, F., and Roy-Byrne, P. P. 1996. Effect of benzodiazepines on plasma levels of homovanillic acid in anxious patients and control subjects. Psychiatry Res. 65:53-59.
28. Charney, D. S., Breier, A., Jatlow, P. I., and Heninger, G. R. 1986. Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: Interactions with yohimbine. Psychopharmacology (Berl) 88:133-140.
29. Lepola, U., Jolkkonen, J., Rimon, R., and Riekkinen, P. 1989. Long-term effects of alprazolam and imipramine on cerebrospinal fluid monoamine metabolites and neuropeptides in panic disorder. Neuropsychobiology 21:182-186.
30. Zemishlany, Z., McQueeney, R., Gabriel, S. M., and Davidson, M. 1990. Neuroendocrine and monoaminergic responses to acute administration of alprazolam in normal subjects. Neuropsychobiology 23:124-128.
31. Pomara, N., Tun, H., Deptula, D., and Greenblatt, D. J. 1998. ApoE-epsilon 4 allele and susceptibility to drug-induced memory impairment in the elderly. J. Clin. Psychopharmacol. 18:179-181.
32. Hixson, J. E. and Vernier, D. T. 1990. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31:545-548.
33. Greenblatt, D. J., Franke, K., and Shader, R. I. 1978. Analysis of lorazepam and its glucuronide metabolite by electron-capture gas-liquid chromatography. Use in pharmacokinetic studies of lorazepam. J. Chromatogr. 146:311-320.
34. Amin, F., Davidson, M., and Davis, K. L. 1992. Homovanillic acid measurement in clinical research: A review of methodology. Schizophr. Bull. 18:123-148.
35. Kopin, I. J., Jimerson, D. C., Markey, S. P., Ebert, M. H., and Polinsky, R. J. 1984. Disposition and metabolism of MHPG in humans: Application to studies in depression. Pharmacopsychiatry 17:3-8.
36. Meltzer, H. 1989. Serotonergic dysfunction in depression. Br. J. Psychiatry Suppl. 25-31.
37. Lambert, G. W. et al. 1995. Regional 5-hydroxyindoleacetic acid production in humans. Life Sci. 57:255-267. (1995).
38. Bertrand, P., Poirier, J., Oda, T., Finch, C. E., and Pasinetti, G. M. 1995. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res. Mol. Brain Res. 33:174-178.
39. Chapman, S. and Michaelson, D. M. 1998. Specific neurochemical derangements of brain projecting neurons in apolipoprotein E-deficient mice. J. Neurochem. 70:708-714.
40. Murphy, G. M., Kremer, C., Rodrigues, H., and Schatzberg, A. F. 2003. The apolipoprotein E varepsilon 4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biol. Psychiatry 54:665-673.
41. Spreux-Varoquaux, O., Alvarez, J. C., Berlin, I., Batista, G., Despierre, P. G., Gilton, A., and Cremniter, D. 2001. Differential abnormalities in plasma 5-HIAA and platelet serotonin concentrations in violent suicide attempters: Relationships with impulsivity and depression. Life Sci. 69:647-657.